Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

Anti-cancer drugs - 1 Feb 2003

Zhai Suoping, Sausville Edward A, Senderowicz Adrian M, Ando Yuichi, Headlee Donna, Messmann Richard A, Arbuck Susan, Murgo Anthony J, Melillo Giovanni, Fuse Eiichi, Figg William D

Abstract excerpt

A phase I trial of flavopiridol administered as a 1-h i.v. infusion schedule was explored. Fifty-five patients were treated with flavopiridol at doses ranging from 12 to 78 mg/m2 daily for 5, 3 and 1 day every 3 weeks. Pharmacokinetic and pharmacodynamic analysis was performed together with analysis of a promoter polymorphism of the UGT1A1 gene. Peak concentrations and areas under the time-concentration curve of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flavonoids

Share to Glucuronosyltransferase

Share to Half-Life

Share to Infusions, Intravenous

Share to Maximum Tolerated Dose

Share to Piperidines

Source

Identifiers

PMID: 12569299
DOI: 10.1097/00001813-200302000-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.PMID 12569299Read ↗

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.Semantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.Semantic proximity Read ↗

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.Semantic proximity Read ↗

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.Semantic proximity Read ↗

A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.Semantic proximity Read ↗

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.